Roche gets FDA emergency use authorization for rapid Coronavirus, flu test

The US Food and Drug Administration on Monday granted Emergency Use Authorization for a rapid version of Roche molecular systems’ Cobas SARS-CoV-2 & Influenza A/B test.

The RT-PCR-based test is designed to simultaneously detect and differentiate SARS-CoV-2, influenza A, and influenza B in healthcare provider-collected nasopharyngeal and nasal swabs, or nasal swabs self-collected in a healthcare setting. The test is designed to run on Roche Molecular Diagnostics’ benchtop Cobas Liat system, providing results for single samples within 20 minutes in either a point-of-care or clinical laboratory setting, according to the company.


Related presentations

Cet article vous a plu ?

Partagez-le sur vos réseaux sociaux